A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Australia

Nucleus Network, Herston, Brisbane